Barrington Research Maintains Outperform on Cross Country Healthcare, Lowers Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Kevin Steinke maintains an Outperform rating on Cross Country Healthcare (NASDAQ:CCRN) but lowers the price target from $21 to $19.
August 08, 2024 | 4:54 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barrington Research analyst Kevin Steinke maintains an Outperform rating on Cross Country Healthcare but lowers the price target from $21 to $19.
The Outperform rating suggests continued confidence in CCRN's performance, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100